Theravance Biopharma, Inc. (NASDAQ:TBPH) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

TBPH has been the subject of a number of other research reports. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. Robert W. Baird reiterated a “sell” rating and set a $22.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Cantor Fitzgerald set a $55.00 price objective on Theravance Biopharma and gave the company a “buy” rating in a research report on Wednesday, October 25th. BidaskClub downgraded Theravance Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Finally, Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a report on Wednesday, August 2nd. Four analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $41.86.

Shares of Theravance Biopharma (TBPH) opened at $28.28 on Tuesday. Theravance Biopharma has a 52-week low of $23.15 and a 52-week high of $43.44. The company has a debt-to-equity ratio of 1.21, a quick ratio of 7.21 and a current ratio of 7.53.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/theravance-biopharma-inc-tbph-lowered-to-sell-at-valuengine/1701286.html.

In other news, EVP Bradford J. Shafer sold 14,670 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total value of $451,395.90. Following the transaction, the executive vice president now directly owns 134,327 shares of the company’s stock, valued at $4,133,241.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Frank Pasqualone purchased 4,000 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was bought at an average cost of $26.34 per share, for a total transaction of $105,360.00. Following the completion of the purchase, the senior vice president now directly owns 213,180 shares of the company’s stock, valued at approximately $5,615,161.20. The disclosure for this purchase can be found here. Corporate insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. QS Investors LLC acquired a new position in shares of Theravance Biopharma in the second quarter worth $100,000. Ameritas Investment Partners Inc. increased its stake in shares of Theravance Biopharma by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 230 shares during the last quarter. Aperio Group LLC acquired a new position in shares of Theravance Biopharma in the second quarter worth $205,000. BNP Paribas Arbitrage SA increased its stake in shares of Theravance Biopharma by 570.7% in the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 4,383 shares during the last quarter. Finally, Amalgamated Bank acquired a new position in shares of Theravance Biopharma in the second quarter worth $214,000. 84.55% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.